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Abstract
Objectives. The use of endoscopic approaches for sinonasal
malignancy resection has increased, but survival data are lim-
ited secondary to disease rarity and new surgical technique.
Here we present a systematic review and meta-analysis of
endoscopic endonasal resection of sinonasal malignancy.
Data Sources. MEDLINE, PubMed Central, NCBI Bookshelf,
Cochrane Library, clinicaltrials.gov, National Guideline Clearinghouse.
Review Methods. PRISMA/MOOSE guidelines were followed.
MeSH terms were ‘‘endoscopic’’ AND (‘‘esthesioneuroblastoma’’
OR ‘‘sinonasal adenocarcinoma’’ OR ‘‘squamous cell carcinoma’’
OR ‘‘sinonasal undifferentiated carcinoma’’). For studies in which
individual-level data were available, results were obtained by
direct pooling. For studies in which only summary Kaplan-Meier
curves were available, numerical data were extracted, traced,
and aggregated by fitting a Weibull model.
Results. Of 320 studies identified, 35 case series were included
(n = 952 patients), with 15 studies analyzed via aggregate mod-
eling and 20 studies analyzed via direct pooling. Two- and
5-year survival rates for patients in aggregate modeling
were 87.5% and 72.3%, respectively (mean follow-up: 32.9
months). Two- and 5-year survival for patients in direct pool-
ing were 85.8% and 83.5%, respectively (mean follow-up: 43.0
6 19.5 months). Significant overall survival difference was
found between low- and high-grade cancers (P = .015) but
not between low- and high-stage cancers (P = .79).
Conclusion. Overall 2- and 5-year survival rates are compara-
ble and sometimes greater than those from open craniofacial
resection. Survival rates significantly differ by cancer grade
but not stage. Journals and investigators should be encour-
aged to publish retrospective and prospective case series
with staged survival updates based on established guidelines.
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T
he expanded endonasal approach has allowed for extir-
pation of benign sinonasal tumors via minimally inva-
sive techniques since the first series published by Jho
and Carrau in 1996.1 While expanded endonasal approach
indications continue to broaden for benign disease processes,
open craniofacial resection continues to be the gold standard
for extirpation of malignant sinonasal tumors. The preference
of open technique is often driven by the desire for an en bloc
resection of tumor with negative margins rather than a progres-
sive resection with negative margins. Additional concerns
include ensuring adequate hemostasis while minimizing vascu-
lar, soft tissue, and dural injury, along with operator familiarity
with endoscopic technology.2-4 However, nearly 2 decades
have passed since the introduction of endoscopic technology,
and with continued advancement in endoscopic hemostatic
techniques, reconstructive options, and standardized safety pre-
cautions, its use in malignant disease resection continues to
rise.5-9
Malignant sinonasal cancer comprises a variety of rare
heterogeneous disease processes, with reported incidences
\1.5 per 100,000 in men and\1 per 100,000 in women.10
The rarity and high degree of heterogeneity in these cancers
result in a paucity of evidence-based management.
Published data are relegated to case series with various
sample populations, staging, follow-up periods, surgical
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techniques, and adjuvant therapies. To study the effect of
endoscopic endonasal management of patients with these
rare malignancies in a quantifiable generalizable method,
we conducted a meta-analysis and systematic review of the
current literature.
Methods
Search Methodology
A meta-analysis and systematic review of the literature was
conducted in accordance with PRISMA guidelines
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses).11,12 As many studies were found to be
observational, MOOSE guidelines (Meta-analysis of
Observational Studies in Epidemiology) were also used.13
MEDLINE, PubMed Central, NCBI Bookshelf, Cochrane
Library, clinicaltrials.gov, and the National Guideline
Clearinghouse databases were searched for the following
MeSH terms: ‘‘endoscopic’’ AND (‘‘esthesioneuroblastoma’’
OR ‘‘sinonasal adenocarcinoma’’ OR ‘‘squamous cell carci-
noma’’ OR ‘‘sinonasal undifferentiated carcinoma’’). In addi-
tion, references of retrieved studies were searched to identify
all relevant articles. Studies with the following criteria were
included for analysis: English-language studies with overall
survival outcome data for patients having undergone endo-
scopic or endoscopic-assisted resection of sinonasal malig-
nancy with a mean follow-up of at least 24 months. Studies
with the following criteria were excluded from analysis: previ-
ously reported patient data with significant overlap, pooled
data with patients who had open craniofacial resection that
could not be extracted, patients operated on with only pallia-
tive intent, patients presenting with recurrent cancer, and case
series with \3 patients, as authors of such series may have
insufficient experience with surgical management. If studies
also included results of patients who had open approaches for
resection of sinonasal malignancy, only those patients who had
endoscopic resection were included. A schematic flow diagram
detailing the systematic search is included (Figure 1).
Statistical Analysis
Data were aggregated according to the nature of the available
source data. For studies in which individual-level data were pro-
vided, results were obtained by direct pooling of observations.
For studies in which individual data were not available and only
summary Kaplan-Meier curves were provided, 2 authors
extracted numerical data from the provided graphical data
(R.B.R. and S.B.S.) by tracing via DigitizeIt 2.0 software
(DigitizeIt, Braunschweig, Germany), as previously described.14
These curves were then aggregated by fitting a Weibull model
to the resultant data points. A random effects framework
allowed for interstudy heterogeneity in outcomes.15 If a study
provided both Kaplan-Meier curves and individual data, the
latter were preferentially collected over numeric data extraction
and model creation. For all studies, accompanying demographic
data were collected for individual or pooled samples of patients.
Given the greater detail of the pooled individual data
subset, additional data points were extracted from these
studies, including cancer staging. Cancer staging was then
separated into ‘‘low stage,’’ defined as American Joint
Committee on Cancer (AJCC) stages T1/T2 or Kadish stages
A/B, and ‘‘high stage,’’ defined as AJCC stages T3/T4 or
Kadish stages C/D.16 Overall mortality was compared on the
basis of stage via a log-rank test. Histopathologic grading was
also studied. ‘‘High grade’’ malignancies included the follow-
ing: squamous cell carcinoma (including that originating from
inverted papilloma), melanoma, sinonasal undifferentiated car-
cinoma, meibomian gland carcinoma, sarcoma, and spindle
cell carcinoma. Overall mortality was compared according to
histopathologic grading via a log-rank test. Differences in his-
topathology between aggregate model and pooled analyses
were tested with a 2-tailed Fisher’s exact test. Differences
between patients in surgery and surgery and radiotherapy
groups in regard to staging and grading were tested with a 2-
tailed Fisher’s exact test. All data analyses were performed in
Stata 13.1 (StataCorp, College Station, Texas).
Results
Of 320 initial search results, 61 full-text articles were
assessed for eligibility, and 35 studies were ultimately
included for systematic review and meta-analysis.17-52 A
total of 952 patients were included. Fifteen studies (n = 759,
79.7%) provided only summary Kaplan-Meier curves,
allowing only for aggregate model analysis, summarized in
Table 1 and illustrated in an aggregated Kaplan-Meier
curve in Figure 2. Twenty studies (n = 193 patients,
20.2%) provided individual-level data, allowing for direct
pooling of observations, summarized in Table 2 and illu-
strated in a pooled Kaplan-Meier curve in Figure 3 (for
complete individual-level data, see Table S1 at www.oto-
journal.org/supplemental). Individual-level data were then
further classified into low- and high-stage disease and strati-
fied by histopathology (Table 3).
Overall 2- and 5-year survival rates for patients in the
aggregate model analysis were 87.5% and 72.3%, respec-
tively. Mean follow-up for studies in the aggregate model
analysis was 33.9 months. Of 759 patients, 684 patients had
purely endoscopic surgical management of disease (90%),
while 75 patients had endoscopic-assisted surgical manage-
ment (9.9%). The majority of patients were male (64%),
and the mean age was 61.4. The most prevalent histopathol-
ogies were sinonasal adenocarcinoma (56%), sinonasal mel-
anoma (13%), and squamous cell carcinoma (11%).
Overall 2- and 5-year survival rates for patients in the
direct pooled analysis were 85.8% and 83.5%, respectively.
Follow-up (mean 6 SD) for studies in the pooled analysis
was 43.0 6 19.5 months. Of 193 patients, 157 patients had
purely endoscopic surgical management of disease (78%),
while 36 had endoscopic-assisted surgical management
(19%). The majority of patients were male (64%), and the
mean age was 56.6 6 8.1 years. The most prevalent histo-
pathologies were esthesioneuroblastoma (32%), sinonasal
adenocarcinoma (28%), and sinonasal melanoma (18%).
Given the greater detail of the pooled individual data
subset, additional analysis was done on this group of patients.
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The majority of patients in the pooled analyses had low-stage
cancer (63%), although staging data were not available for
22% of the malignancies (Table 3). The majority of esthesio-
neuroblastomas (61%), sinonasal adenocarcinomas (73%), and
squamous cell carcinomas 6 inverted papilloma (74%) were
low-stage malignancies. Sinonasal undifferentiated cancers rep-
resented the only disease process with a majority of high-stage
malignancies (67%). For the majority of melanomas and more
uncommon malignancies included, staging data were unavail-
able. No significant difference in overall survival between
low- and high-stage cancers was found (P = .79; Figure 4).
Histopathologic grading was also studied. Among the high-
grade malignancies, the most common were squamous cell
carcinoma (51.9%), melanoma (22.6%), and sarcoma (7.7%),
while among the low-grade malignancies, the most common
were sinonasal adenocarcinoma (61.0%) and esthesioneuro-
blastoma (12.7%; Table 4). A significant survival difference
between high- and low-grade cancer was found (P = .015;
Figure 5).
Last, survival analysis was performed on patients who
received radiotherapy in addition to surgery. No statistically
significant difference in overall survival was found between
those patients who only underwent surgery and those
patients who underwent surgery and radiotherapy (P = .85;
Figure 6). These 2 groups (surgery only versus surgery 1
radiotherapy) were compared to assess whether an unequal
distribution of patients was confounding survival rates
based on tumor stage and grade. The 2 groups were signifi-
cantly different according to stage: in the surgery-only
cohort, 11.6% of tumors were high stage, and 88.4% of
tumors were low stage, while in the surgery 1 radiotherapy
cohort, 46.7% of tumors were high stage, and 53.3% of
tumors were low stage (P\ .001). The 2 groups were not
significantly different in respect to grading: in the surgery-
only cohort, 33.3% of tumors were high grade, and 66.7%
of tumors were low grade, while in the surgery 1 radiother-
apy cohort, 28.3% of tumors were high grade, and 71.7% of
tumors were low grade (P = .602).
Histopathology differed greatly between analyses. The
aggregate model analyses had a significantly greater preva-
lence of SNAC (sinonasal adenocarcinoma; 56% vs 28%, P\
.0001). The reason for this skew was the large prevalence
of SNAC described in a single multicenter study from
France (n = 159, 49%).17 Because of this high prevalence
of a single pathology, we sought to reanalyze our data
after exclusion of SNAC. An attempt at data analysis
excluding SNAC was made for studies in the aggregate
model, but this was not feasible, as many studies included
Literature Search:
Databases - MEDLINE, 
PubMed Central, NCBI 
Bookshelf, Cochrane Library, 
clinicaltrials.gov, and The 
Naonal Guideline 
Clearinghouse 
Limits: English language only
Search results combined
n = 320
Arcles screened on basis 
of tle and abstract
Full-text arcles assessed 
for eligibility
n = 61
Pooled: 30
Individual: 31
Excluded (n = 259)
Not pertaining to outcomes of 
endoscopic or endoscopic-assisted 
surgery for newly diagnosed malignant 
anterior skull base cancers: 248
Case reports: 6
Previously reported data: 4
Full text unavailable: 1
Included
n = 35
Pooled : 15
Individual : 20
Excluded (n = 26)
Unable to extract endoscopic -specific data: 3
No overall survival (OS) Kaplan-Meier curve or 
OS individual data: 11
Previously reported data: 3
Mean follow-up <2 years for pernent 
paents: 4
Only  paents with recurrenct cancer: 1
Only surgery with palliave intent: 1
Case series < 3 pernent paents: 3
Figure 1. Flow diagram detailing systematic search.
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Table 1. Studies Included for Aggregate Model Analysis.a
Sex
Source Location Years Patients EO EA Malignancies
Mean
Age, y Male Female
Mean
Follow-up, mo
Antognoni (2015)20 Varese, Italy 2003-2010 30 3 27 SNAC (30) 68.3 28 2 48
Batra (2010)32 Cleveland,
USA
2000-2008 25 25 0 SCC (6), esthesio (5),
mel (5), SNUC (4),
SNAC (1),
leiomyosarcoma (1),
other CAs (3)
57.5 10 15 31.7
Batra (2005)45 Cleveland,
USA
1995-2003 9 9 0 SCC (2), SNAC (2), mel
(2), sarcoma (1), SNUC
(1), adenosquamous CA
(1)
55 6 3 24
de Almeida (2015)21 Pittsburgh,
USA
2000-2012 34 25 9 SCC (34) 57 20 14 33
Eloy (2009)36 Miami, USA 1997-2006 18 18 0 Esthesio (10), adenoid
cystic CA (3), SNUC
(1),
hemangiopericytoma
(3), small cell CA (1)
61.2 10 8 31.7
Goffart (2000)52 Liege and
Leuven,
Belgium
1992-1999 78 66 12 SNAC (40), SCC (13),
mel (7), esthesio (5),
others (13)
62.4 64 14 25.9
Hanna (2009)34 Houston, USA 1992-2007 120 93 27 —b 52.6 65 55 37
Lund (2012)26 London, UK 1963-2010 31 31 0 Mel (31) 65.9b —b —b 37.5b
Lund (2007)41 London, UK Unknown 49 49 0 SNAC (15), mel (11),
esthesio (11), SCC (3),
chondrosarcoma (3),
hemangiopericytoma
(2), malignant
schwannoma (1),
transitional cell CA (1),
adenoid cystic CA (1),
SNUC (1)
60 26 23 21
Luong (2010)29 Cleveland, USA 1998-2007 52 52 0 —b 59b —b —b 38.5
Suh (2013)24 Philadelphia,
USA
2002-2010 36 36 0 SCC (4), SNAC (8),
sarcoma (6), mel (4),
esthesio (5), adenoid
cystic CA (3), SNUC
(1), others (5)
56.7 19 17 39
Swegal (2014)19 Cleveland, USA 1998-2012 12 12 0 Mel (12) 65.5 6 6 32
Van Gerven (2011)31 Leuven, Belgium 1992-2004 44 44 0 SNAC (44) 62 43 1 61
Vergez (2014)17 France
(multicenter)
1998-2010 159 159 0 SNAC (159) 68.9 148 11 32.5
Villaret (2010)30 Brescia/Pavia
and Varese,
Italy
1996-2008 62 62 0 SNAC (36), esthesio
(13), mel (3),
adenoid cystic CA (2),
hemangiopericytoma
(2), SCC (2), others (4)
61.7 44 18 20.5
All 1963-2012c 759 684 75 587 61.4 489 187 33.9
Abbreviations: CA, carcinoma; EA, endoscopically assisted; EO, endoscopic only; esthesio, esthesioneuroblastoma; IP, inverted papilloma; mel, melanoma;
SCC, squamous cell carcinoma; SNAC, sinonasal adenocarcinoma
aValues presented as n or mean. Number of patients reviewed includes only those who met inclusion criteria. The listed studies reviewed more patients than
the number included in our analysis.
bDemographic data for endoscopic population unable to be extracted from overall patient population.
cStudies may predate advent of endoscopic techniques (1991) because patients with open resection were included.
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SNAC among other histopathologies, making non-SNAC
data inextricable. This was easily extracted in the pooled
group, however. In the pooled group, no significant differ-
ence in overall survival between low- and high-stage can-
cers was found even once SNAC was excluded (P = .67;
Figure 7). In the pooled group, there was still a statisti-
cally significant difference in survival between high- and
low-grade malignancies even once SNAC was excluded
(P = .010; Figure 8).
Interextractor reliability in data extraction was excellent.
Estimated 2-year survival was 87.0% with data only from
extractor 1 versus 87.5% for data from extractor 2, while
estimated 5-year survival was 74.7% with extractor 1’s data
versus 72.3% with extractor 2’s data.
Discussion
The Kaplan-Meier overall survival curves and percentages
at 2 and 5 years in patients in the pooled analysis and the
aggregate model analysis provide strong evidence for con-
tinued use and further adoption of endoscopic endonasal
resection of sinonasal malignancy. While open craniofacial
resection remains the gold standard surgical technique for
extirpation of sinonasal malignancy,53 endoscopic resection
may allow for decreased cosmetic deformity, associated
hospital stay, and complication rates. The endoscopic sur-
geon must be able and willing to sacrifice these advantages
and convert to an open approach when necessary to adhere
to oncologic principles, especially that of margin-negative
en bloc resection. Our data support the use of endoscopic
techniques only with adherence to this caveat. Our analysis
does not compare endoscopic resection with open resection,
as no randomized controlled trials exist comparing the 2
surgical modalities. We therefore sought only to quantify
the existing data to determine overall survival rates and
explore possible predictors for increased survival.
Comparing endoscopic management with open craniofa-
cial management is difficult. In the preendoscopic era, a pre-
vious systematic review by Dulguerov et al in 2001 outlined
overall survival rates of sinonasal malignancy throughout the
decades, showing survival rates of 28% 6 13% in the 1960s,
36% 6 13% in the 1970s, 43% 6 15% in the 1980s, and
51% 6 14% in the 1990s.54 Patients treated prior to the
1990s could not have been treated endoscopically; as such,
our data show excellent continuation of this upward trend of
overall survival rates. Comparisons with such historical data
may be misleading, however, as multiple confounding factors
undoubtedly played a role, such as increased training stan-
dards, differences in staging, standardized measures (preo-
perative, operative, and postoperative), adjunctive therapies,
and better diagnostic modalities. A more recent systematic
review by Higgins et al in 2011 shows overall 5-year survival
rates of open craniofacial resection at 55.2% (n = 101).16 Our
5-year survival rates of 72.3% and 83.5% are therefore
encouraging.
Our aggregate and pooled model overall survival out-
comes were similar for the 2-year benchmark (87.5% vs
85.8%) but somewhat different for the 5-year benchmark
(72.3% vs 83.5%). As noted earlier, the aggregate analysis
had a significantly increased proportion of SNAC as com-
pared with the pooled analysis largely due to one French
multicenter study (56% vs 28%, P\ .0001). In this study,
the overall 5-year survival rate was 62% and likely skewed
the overall survival rate of the aggregate model.17 SNAC
has historically been further classified into intestinal-type
adenocarcinomas and nonintestinal-type adenocarcinomas,
with varying survival outcomes for each histologic type, but
the authors did not explicitly stratify their results by these
groupings, possibly also confounding survival out-
comes.53,55 To determine whether SNAC prevalence con-
founded the results for our pooled analysis, we repeated
survival analysis by stage (Figures 4, 7) and grade
(Figures 5, 8) excluding patients with SNAC, but our
results were comparable for these secondary subanalyses.
Based on the smaller, pooled analysis of patients, stage
had a nonsignificant effect on overall survival outcomes
when based on endoscopic surgical techniques. Upon closer
inspection, however, this may be misleading for 2 reasons:
sinonasal undifferentiated carcinoma was the only histo-
pathology type with a majority of high-stage cancers (67%),
and staging for sinonasal melanoma, a particularly fatal dis-
ease, was unavailable for 18 of the 20 patients and therefore
could not be included in this analysis.56 Indeed, mucosal
melanoma by definition is high stage, as staging begins at
T3 according to the latest AJCC guidelines.57
According to our data, histopathologic grade does have a
significant effect on overall survival outcomes. As noted
earlier, skull base malignancies encompass a variety of his-
topathology, and classifying these malignancies into low-
and high-grade subtypes may allow for better counseling for
patients in regard to survival outcomes.10,53
Other variables were also initially considered for study in
the pooled data analysis, including disease-specific survival,
recurrence-free survival, previous therapy, metastasis/nodal
status, and extent/location of disease process. However,
published data were too variable in reporting of these out-
comes; therefore, we were confined in our ability to draw
Figure 2. Kaplan-Meier overall survival curve of patients in aggre-
gate model analysis (n = 15 studies, n = 759 patients).
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conclusions solely based on overall survival and cancer
stage.
It is important to note that 112 patients included in the
study (10.9%) had ‘‘endoscopic assisted’’ surgery. The defini-
tion of endoscopic-assisted surgery was also variable, some-
times including orbital incision, frontal/subfrontal craniotomy,
or anterior craniotomy.34,49,52 It is theoretically possible that
these endoscopic-assisted techniques allowed for greater access
and visualization of the sinonasal malignancy, artificially
increasing overall survival rates for some studies. It is difficult
to generalize conclusions for this subset of the population.
The effect of radiation therapy with or without chemotherapy
after surgery cannot be underestimated. Although indications for
adjuvant therapy differ from institution to institution, it is gener-
ally reserved for patients with high-grade tumors, advanced
tumor stage, bone invasion, perineural spread, intracranial
extension, dural or brain involvement, and/or positive mar-
gins.34 In addition, controversy exists for elective neck dis-
section or elective radiotherapy.58
At first glance, our data seem to indicate that adjuvant
radiation therapy did not result in a statistically significant
survival benefit, but there were significantly higher numbers
of patients with high-stage tumors in the surgery 1 radiotherapy
Table 4. Histopathology of Tumors in Pooled Model Analysis
Stratified by Grade.a
Studies, n (%)
Grade Aggregate (n = 693) Pooled (n = 186)
Low
Esthesioblastoma 74 61
SNAC 355 54
Adenoid cystic carcinoma 18 3
Hemangiopericytoma 7 2
Chondrosarcoma 5 3
Total 459 (66.2) 123 (66.1)
High
Squamous cell carcinoma 127 27
Melanoma 67 20
SNUC 12 15
Sarcoma 23 1
Neuroendocrine 5 0
Total 234 (33.8) 63 (33.9)
Abbreviations: SNAC, sinonasal adenocarcinoma; SNUC, sinonasal undiffer-
entiated carcinoma.
aMore uncommon malignancies that were present but excluded from analysis
of tumor grade included the following: leiomyosarcoma, clear cell carcinoma,
basal cell carcinoma, angiomyxoid neoplasm, angiosarcoma, osteosarcoma,
spindle cell carcinoma, nonspecified carcinoma, carcinoma ex pleomorphic
adenoma, poorly differentiated carcinoma, teratocarcinoma, plasmacytoma,
teratocarcinoma, fibrosarcoma, extrapleural solitary fibrous tumor, small cell
carcinoma, malignant schwannoma, and transitional cell carcinoma.
Table 3. Histopathology of Tumors in Pooled Model Analysis
Stratified by Stage.
Low Stage High Stage N/A Total
Esthesioneuroblastoma 36 23 2 61
SNAC 37 14 3 54
SCC 12 3 2 17
SCC 1 IP 2 2 6 10
Melanoma 2 0 18 20
SNUC 5 10 0 15
Adenoid cystic carcinoma 1 2 0 3
Othera 0 1 12 13
Total 95 55 43 193
Abbreviations: IP, inverted papilloma; N/A, not applicable; SCC, squamous
cell carcinoma; SNAC, sinonasal adenocarcinoma; SNUC, sinonasal undiffer-
entiated carcinoma.
aOther malignancy types include chondrosarcoma (3), chordoma (1),
hemangiopericytoma (2), leiomyosarcoma (2), malignant peripheral nerve
sheath tumor (1), Meibomian gland carcinoma (1), plasmocytoma (1), sar-
coma (1), and spindle cell carcinoma (1).
Figure 3. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis (n = 193 patients).
Figure 4. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis stratified by cancer stage (n = 193 patients).
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cohort as compared with the surgery-only cohort. Our results
therefore continue to support the use of multimodality therapy
for low- and high-stage tumors. There were no differences in
patient distribution in regard to tumor grade. Further prospective
trials are therefore needed to evaluate whether patients with
low-grade tumors would benefit from multimodality therapy.
For now, the most important factor for multimodality therapy
remains the presence of a multidisciplinary skull base team to
decide on therapeutic options for patients with these rare malig-
nancies in a case-by-case scenario.
Conclusions based on systematic reviews and meta-
analyses are limited by several factors. Publication bias may
have allowed for investigators with the largest case series to
be published. rather than those with smaller case series and
less experience, as has been noted.59 If so, our data set may
have an artificially inflated survival rate due to high-volume
experience with resection of sinonasal malignancy. When
compounded with the inherent referral bias of tertiary and
quaternary skull base centers, our published survival rates
may not be generalizable to smaller skull base practices. In
addition, during data collection, all attempts were made to
not include studies that had a significant amount of previ-
ously reported data, but it is possible that results of several
patients may have been repeated, especially as authors may
have changed institutions and/or reported results twice, as
some included studies were multi-institutional.
Sinonasal malignancy is heterogeneous, and our data sup-
port epidemiologic studies describing variations in preva-
lence and presentation throughout the world.55 Pooled
analyses offer an advantage in allowing increased sample
sizes for data analysis and a disadvantage in that conclu-
sions may not always be applicable to populations with a
high degree of heterogeneity in cancer subtypes.13 This
pooled analysis attempts to mitigate the retrospective limita-
tions of nonrandomized treatment selection by offering a
global perspective.54
Figure 8. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis stratified by cancer grade excluding sinona-
sal adenocarcinoma (n = 193 patients).
Figure 7. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis stratified by cancer stage excluding sinonasal
adenocarcinoma (n = 193 patients).
Figure 6. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis stratified by type of intervention (n = 193
patients).
Figure 5. Kaplan-Meier overall survival curve of patients in pooled
individual data analysis stratified by cancer grade (n = 193 patients).
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Although retrospective comparisons between open and
endoscopic surgical methods have been attempted, an ideal
comparison would include a multicenter prospective rando-
mized controlled trial for open versus endoscopic techniques
with stratification by histopathology and staging. This is
unlikely to happen due to worldwide rarity of disease, sur-
geon preference and comfort with surgical technique, and
variation in presentation and anatomic location of disease.
Instead, we urge investigators to publish further prospective
and retrospective case series with staged survival updates
concerning patient cohorts. As journals have done by requir-
ing investigators to adhere to the CONSORT guideline for
reporting randomized controlled trials, they should require
investigators to report observational studies in a standardized
fashion using PRISMA or MOOSE guidelines.12,13,60 In this
way, information may not be missed, such as adjuvant ther-
apy, location, staging, margin status, and recurrence. Journals
may require investigators to summarize their results for the
body of the journal article, but they should encourage investi-
gators to explicitly submit individual data in appendices and
supplements. Only in this way will we be able to continue to
draw evidence-based conclusions regarding endoscopic surgi-
cal management of sinonasal malignancy.
Conclusion
Overall 2- and 5-year survival rates of endoscopic endonasal
resection of sinonasal malignancy are comparable and
sometimes greater than the published literature for open cra-
niofacial resection of sinonasal malignancy. Survival rates
of endoscopic endonasal resection appear to significantly
correlate with cancer grading but not with cancer staging.
Journals and investigators should be encouraged to publish
retrospective and prospective case series with staged sur-
vival updates based on established guidelines to provide
outcomes that may be used in future systematic reviews and
meta-analysis.
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